Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ly-3009120. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 15/20 | 1.00 |
| ▸ | BRAF known ✓ | P15056 | 13/20 | 1.00 |
| ▸ | ARAF known ✓ | P10398 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | KRAS | P01116 | 8/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 1/20 | 1.00 |
| ▸ | CSK | P41240 | 1/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 1/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 1/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ly-3009120 SCHEMBL29479162 | 1.00 | RAF1 (1.00) | RAF1BRAFKDRKRASARAF | |
| Ly-3009120 SCHEMBL15241297 | 1.00 | RAF1 (1.00) | RAF1BRAFKDRKRASARAF | |
| SCHEMBL16667656 | 0.95 | RAF1 (0.90) | RAF1BRAFKDRKRASARAF | |
| SCHEMBL16667641 | 0.94 | RAF1 (0.88) | RAF1BRAFKDRKRASARAF | |
| SCHEMBL16667662 | 0.93 | RAF1 (0.87) | RAF1BRAFKDRKRASARAF | |
| SCHEMBL16667679 | 0.92 | RAF1 (0.85) | RAF1BRAFKDRKRASARAF | |
| SCHEMBL15270314 | 0.92 | RAF1 (0.85) | RAF1BRAFKDRKRASARAF | |
| SCHEMBL16667703 | 0.92 | RAF1 (0.84) | RAF1BRAFKDRKRASARAF | |
| SCHEMBL15269840 | 0.91 | RAF1 (0.84) | RAF1BRAFKDRKRASARAF | |
| SCHEMBL16667688 | 0.90 | BRAF (0.82) | RAF1BRAFKDRKRASARAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| EP-4587026-A1 | COMBINATIONS | Recurium IP Holdings, LLC (US) | 2025-07-23 | — | — | EP | claimed |
| US-20250205240-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC | 2025-06-26 | — | — | US | claimed |
| CN-120202008-A | Combination of two or more kinds of materials | 里科瑞尔姆IP控股有限责任公司 | 2025-06-24 | — | — | CN | claimed |
| CN-116036278-B | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | claimed |
| US-20240132551-A1 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIV MASSACHUSETTS (US) | 2024-04-25 | — | — | US | claimed |
| CN-117731786-A | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2024-03-22 | — | — | CN | claimed |
| WO-2024059696-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC (US) | 2024-03-21 | — | — | WO | claimed |
| CN-111053768-B | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-116036278-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20220117950-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. | 2022-04-21 | — | — | US | disclosed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | RAF1 2779/4885BRAF 3001/4885ARAF 3216/4885 |
| US-20220117950-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | MAP3K1, MAP3K2, MAP3K6 | RAF1 35/4885BRAF 40/4885ARAF 94/4885 |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MAP3K1, MAP3K2, MAP3K6 | RAF1 35/4885BRAF 40/4885ARAF 94/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | RAF1 50/4885BRAF 1/4885ARAF 66/4885 |
| US-20250205240-A1 | COMBINATIONS | MCL1, TP53, BRCA1 | RAF1 1437/4885BRAF 321/4885ARAF 3376/4885 |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MOK, TTK, MAPK4 | RAF1 79/4885BRAF 11/4885ARAF 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.